Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical evaluation of rosiglitazone malate (BRL49653C) in patients with type 2 diabetes mellitus (monotherapy) - double-blind comparative study of rosiglitazone maleate vs. pioglitazone hydrochloride and placebo -

Trial Profile

Clinical evaluation of rosiglitazone malate (BRL49653C) in patients with type 2 diabetes mellitus (monotherapy) - double-blind comparative study of rosiglitazone maleate vs. pioglitazone hydrochloride and placebo -

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2018

At a glance

  • Drugs Rosiglitazone (Primary) ; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 15 Oct 2008 Actual start date changed from Dec 2005 to Jan 2006 as reported by ClinicalTrials.gov.
    • 10 Aug 2007 Status changed from in progress to completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top